Literature DB >> 32518857

Opportunities for improving cancer treatment using systems biology.

Jason I Griffiths1, Adam L Cohen2, Veronica Jones3, Ravi Salgia4, Jeffrey T Chang5, Andrea H Bild6.   

Abstract

Current cancer therapies target a limited set of tumor features, rather than considering the tumor as a whole. Systems biology aims to reveal therapeutic targets associated with a variety of facets in an individual's tumor, such as genetic heterogeneity and its evolution, cancer cell-autonomous phenotypes, and microenvironmental signaling. These disparate characteristics can be reconciled using mathematical modeling that incorporates concepts from ecology and evolution. This provides an opportunity to predict tumor growth and response to therapy, to tailor patient-specific approaches in real time or even prospectively. Importantly, as data regarding patient tumors is often available from only limited time points during treatment, systems-based approaches can address this limitation by interpolating longitudinal events within a principled framework. This review outlines areas in medicine that could benefit from systems biology approaches to deconvolve the complexity of cancer.

Entities:  

Year:  2019        PMID: 32518857      PMCID: PMC7282416          DOI: 10.1016/j.coisb.2019.10.018

Source DB:  PubMed          Journal:  Curr Opin Syst Biol        ISSN: 2452-3100


  97 in total

Review 1.  Detecting diversity: emerging methods to estimate species diversity.

Authors:  Kelly J Iknayan; Morgan W Tingley; Brett J Furnas; Steven R Beissinger
Journal:  Trends Ecol Evol       Date:  2013-12-05       Impact factor: 17.712

Review 2.  Does rapid evolution matter? Measuring the rate of contemporary evolution and its impacts on ecological dynamics.

Authors:  Stephen P Ellner; Monica A Geber; Nelson G Hairston
Journal:  Ecol Lett       Date:  2011-04-24       Impact factor: 9.492

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 4.  Targeting protein kinases to reverse multidrug resistance in sarcoma.

Authors:  Hua Chen; Jacson Shen; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2015-12-08       Impact factor: 12.111

Review 5.  Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment.

Authors:  Senthil Rajappa; M Vamshi Krishna; Prasad Narayanan
Journal:  Adv Ther       Date:  2019-04-02       Impact factor: 3.845

6.  Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma.

Authors:  Peiwen Chen; Di Zhao; Jun Li; Xin Liang; Jiexi Li; Andrew Chang; Verlene K Henry; Zhengdao Lan; Denise J Spring; Ganesh Rao; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Cell       Date:  2019-06-10       Impact factor: 31.743

Review 7.  The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination.

Authors:  Myriam Labelle; Richard O Hynes
Journal:  Cancer Discov       Date:  2012-11-19       Impact factor: 39.397

8.  DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.

Authors:  Benedict Anchang; Kara L Davis; Harris G Fienberg; Brian D Williamson; Sean C Bendall; Loukia G Karacosta; Robert Tibshirani; Garry P Nolan; Sylvia K Plevritis
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-13       Impact factor: 11.205

Review 9.  Computational models for predicting drug responses in cancer research.

Authors:  Francisco Azuaje
Journal:  Brief Bioinform       Date:  2017-09-01       Impact factor: 11.622

Review 10.  Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).

Authors:  Ewa Maj; Diana Papiernik; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2016-09-26       Impact factor: 5.650

View more
  2 in total

Review 1.  Group Behavior and Emergence of Cancer Drug Resistance.

Authors:  Supriyo Bhattacharya; Atish Mohanty; Srisairam Achuthan; Sourabh Kotnala; Mohit Kumar Jolly; Prakash Kulkarni; Ravi Salgia
Journal:  Trends Cancer       Date:  2021-02-20

2.  Path to Clonal Theranostics in Luminal Breast Cancers.

Authors:  Nawale Hajjaji; Soulaimane Aboulouard; Tristan Cardon; Delphine Bertin; Yves-Marie Robin; Isabelle Fournier; Michel Salzet
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.